Amarin Receives National Reimbursement for VAZKEPA® in Italy

Core Insights - Italy's National Health Service has approved VAZKEPA® (icosapent ethyl) for national reimbursement aimed at reducing cardiovascular risk in eligible high-risk patients, marking Italy as the third EU5 market to grant such reimbursement and the ninth overall in Europe [1][4] - The approval is part of a broader strategy by Amarin Corporation to enhance reimbursement, access, and commercialization in Europe, which has resulted in securing national reimbursement in three EU5 markets and nine European markets overall, covering more than 50% of the established cardiovascular disease population in Western Europe [4][6] - The intellectual property for VAZKEPA in Europe has been extended to 2039, eliminating the risk of early competitive entry prior to patent expiration [5] Industry Context - Cardiovascular disease is the leading cause of death and hospitalization in Italy, with over 217,000 deaths and more than 107,000 hospitalizations annually due to myocardial infarction, indicating a significant need for effective treatment options [2][3] - The approval of VAZKEPA addresses a critical clinical need for patients with established cardiovascular disease and elevated triglycerides, who are at a higher risk of subsequent cardiovascular events despite well-managed LDL-C levels [3] - The endorsement of VAZKEPA by over 50 medical societies globally and its approval in 46 countries for cardiovascular risk reduction highlight the significant potential to benefit millions of patients worldwide [6]